Palisade Bio reports Q2 2026 net loss $10.6M; advances PALI-2108 into Phase 2

PALISADE BIO, INC.

2026-Q2 EPS reported -$0.10 revenue$500,000

Q2 2026 net loss $10.6M ($0.05/share) vs $2.8M ($0.58) year ago; R&D spend $7.4M vs $1.7M.
Cash $125.2M at June 30, 2026; funded through Phase 2 readouts (UC 2H 2027, CD early 2028).
Phase 1 PALI-2108: 5/5 UC clinical response, 2/5 remission; FSCD SES-CD reduced ~47.5% (3.8 points).
Phase 2 ASCENTRA-UC enrollment expected 2H 2026; ASCENTRA-CD IND expected 2H 2026, trial start 1Q 2027.
Board adds Robert Baltera and Jordan Zwick; $0.5M license revenue milestone from Newsoara.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.